Skip to main content
  • More from ADA
    • Diabetes
    • Clinical Diabetes
    • Diabetes Spectrum
    • ADA Standards of Medical Care
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care
  • Subscribe
  • Log in
  • My Cart
  • Follow ada on Twitter
  • RSS
  • Visit ada on Facebook
Diabetes Care

Advanced Search

Main menu

  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • Special Article Collections
    • ADA Standards of Medical Care
  • Browse
    • By Topic
    • Issue Archive
    • Saved Searches
    • Special Article Collections
    • ADA Standards of Medical Care
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
    • Guidance for Reviewers
  • Reprints/Reuse
  • Advertising
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Special Podcast Series: Therapeutic Inertia
    • Special Podcast Series: Influenza Podcasts
    • Special Podcast Series: SGLT2 Inhibitors
    • Special Podcast Series: COVID-19
  • Submit
    • Submit a Manuscript
    • Journal Policies
    • Instructions for Authors
    • ADA Peer Review
  • More from ADA
    • Diabetes
    • Clinical Diabetes
    • Diabetes Spectrum
    • ADA Standards of Medical Care
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care

User menu

  • Subscribe
  • Log in
  • My Cart

Search

  • Advanced search
Diabetes Care
  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • Special Article Collections
    • ADA Standards of Medical Care
  • Browse
    • By Topic
    • Issue Archive
    • Saved Searches
    • Special Article Collections
    • ADA Standards of Medical Care
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
    • Guidance for Reviewers
  • Reprints/Reuse
  • Advertising
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Special Podcast Series: Therapeutic Inertia
    • Special Podcast Series: Influenza Podcasts
    • Special Podcast Series: SGLT2 Inhibitors
    • Special Podcast Series: COVID-19
  • Submit
    • Submit a Manuscript
    • Journal Policies
    • Instructions for Authors
    • ADA Peer Review
Emerging Treatments and Technologies

Reduced Mortality Associated With the Use of ACE Inhibitors in Patients With Type 2 Diabetes

  1. Dean T. Eurich, BSP, MSC12,
  2. Sumit R. Majumdar, MD, MPH, FRCPC13,
  3. Ross T. Tsuyuki, PHARMD, MSC14 and
  4. Jeffrey A. Johnson, PHD12
  1. 1Institute of Health Economics, Edmonton, Alberta, Canada
  2. 2Department of Public Health Sciences, University of Alberta, Edmonton, Alberta, Canada
  3. 3Division of General Internal Medicine, Department of Medicine, University of Alberta, Edmonton, Alberta, Canada
  4. 4Division of Cardiology, Department of Medicine, University of Alberta, Edmonton, Alberta, Canada
  1. Address correspondence and reprint requests to Dr. Jeffrey A. Johnson, #1200, 10405 Jasper Ave., Edmonton, AB, Canada T5J 3N4. E-mail: jeff.johnson{at}ualberta.ca
Diabetes Care 2004 Jun; 27(6): 1330-1334. https://doi.org/10.2337/diacare.27.6.1330
PreviousNext
  • Article
  • Figures & Tables
  • Suppl Material
  • Info & Metrics
  • PDF
Loading

Abstract

OBJECTIVE—ACE inhibitor therapy is widely used in lower-risk patients with type 2 diabetes to reduce mortality, despite limited evidence to support this clinical strategy. The aim of this study was to evaluate the association between ACE inhibitor use and mortality in patients with diabetes and no cardiovascular disease.

RESEARCH DESIGN AND SETTINGS—Using the Saskatchewan health databases, 12,272 new users of oral hypoglycemic agents were identified between the years of 1991 and 1996. We excluded 3,202 subjects with previous cardiovascular disease. Of the remaining subjects, 1,187 “new users” of ACE inhibitors were identified (ACE inhibitor cohort). Subjects not receiving ACE inhibitor therapy throughout the follow-up period served as the control cohort (n = 4,989). Subjects were prospectively followed until death or the end of 1999. Multivariate Cox proportional hazards models were used to assess differences in all-cause and cardiovascular-related mortality between cohort groups.

RESULTS—Subjects were 60.7 ± 13.7 years old, 43.6% female, and were followed for an average of 5.3 ± 2.1 years. Mean duration of ACE inhibitor therapy was 3.6 ± 1.8 years. We observed significantly fewer deaths in the ACE inhibitor group (102 [8.6%]) compared with the control cohort (853 [17.1%]), with an adjusted hazard ratio (HR) and 95% CI of 0.49 (0.40–0.61) (P < 0.001). Cardiovascular-related mortality was also reduced (40 [3.4%] vs. 261 [5.2%], adjusted HR, 0.63 [0.44–0.90]; P = 0.012).

CONCLUSIONS—The use of ACE inhibitors was associated with a significant reduction in all-cause and cardiovascular-related mortality in a broad spectrum of patients with type 2 diabetes and no cardiovascular disease.

  • CDS, Chronic Disease Score
  • HOPE, Heart Outcomes Prevention Evaluation

Mortality in individuals with type 2 diabetes is mainly attributed to the macrovascular complications of cardiovascular and cerebrovascular disease (1,2). Although aggressive management of hypertension, lipids, smoking cessation, and blood glucose are emphasized in recent guidelines, these traditional risk factors do not fully account for the higher prevalence and severity of cardiovascular disease in individuals with type 2 diabetes (3,4). As a result, novel risk factors, such as activation of the renin-angiotensin-aldosterone system, are being examined (5). Evidence from large-scale clinical trials has suggested that attenuation of the renin-angiotensin-aldosterone system by ACE inhibitors may reduce cardiovascular morbidity and mortality in patients with established cardiovascular disease (5–8).

There have been, to our knowledge, no studies designed to directly evaluate the effects of ACE inhibitors on cardiovascular disease in patients with diabetes. Thus, the evidence available to guide clinical decision making is based on subgroup analyses of larger trials (7,8). For example, the Heart Outcomes Prevention Evaluation (HOPE) study (8) was designed to study the effects of the ACE inhibitor, ramipril, in 9,297 high-risk individuals (38% with diabetes). Over a median follow-up of 4.5 years, patients who received ramipril had a 22% reduction in the primary outcome of myocardial infarction, stroke, or death from cardiovascular causes. In addition, there were 26 and 16% reductions in cardiovascular-related death and death from any cause, respectively, in favor of the ramipril group. Although HOPE provided clear evidence of the benefits of ACE inhibitors, it is important to note that only 20% of individuals enrolled were clinically free of cardiovascular disease at baseline. A subgroup analysis of these 1,135 patients (99% with diabetes) did not show a beneficial effect of treatment with ramipril, although this particular subgroup analysis was both post hoc and underpowered (8,9). Similar results, limited to subgroup analyses, have also been shown (7) in other higher-risk populations exposed to ACE inhibitors.

Currently, ACE inhibitor therapy is widely used for patients with type 2 diabetes, including those at lower risk, despite limited evidence to support this clinical strategy. Therefore, it is unlikely that a randomized, placebo-controlled trial with ACE inhibitors will be conducted in this population. Accordingly, we conducted a large, population-based, observational study to test the hypothesis that ACE inhibitor use would be associated with reduced all-cause and cardiovascular-related mortality in a broad range of patients with type 2 diabetes without clinical cardiovascular disease.

RESEARCH DESIGN AND METHODS

Subjects eligible for inclusion into our study cohorts were registered beneficiaries of Saskatchewan Health between 1 January 1991 and 31 December 1996, aged ≥30 years, and had at least 1 year of continuous coverage in the provincial health insurance plan.

The Saskatchewan Health insurance plan provides universal health coverage for essentially all residents (∼1 million people) in the Province of Saskatchewan. Approximately 9% of the population is not eligible for prescription drug benefits through Saskatchewan Health. Most notably, this includes federal employees (e.g., Royal Canadian Mounted Police), federal inmates, and Registered Indians (10).

From this pool of potential subjects, we identified 12,272 first-time users of oral hypoglycemic agents based on prescription claims for a sulfonylurea or metformin (hereafter referred to as newly treated patients with diabetes) (11). We then categorized this population with newly treated diabetes according to their use of ACE inhibitors: 6,557 (53.4%) subjects were classified into the new ACE inhibitor user cohort based on prescription claims for ACE inhibitors from 1 January 1991 through 31 December 1999 or into our control cohort of ACE inhibitor nonusers (n = 5,715; 46.6% of sample).

To control for baseline risk of cardiovascular disease before the diagnosis of diabetes or initiation of ACE inhibitor therapy, we excluded subjects (n = 3,202) with established cardiovascular diagnoses based on either a 3-year prior hospital separation history for cardiovascular disease (online appendix [available at http://care.diabetesjournals.org]) or prescription claims directed at symptomatic coronary heart disease (nitrates) or congestive heart failure (loop diuretics) (12–15). Individuals exposed to ACE inhibitors before the initiation of their oral hypoglycemic agents were also excluded (n = 1,559). Finally, 1,335 (10.9%) subjects were excluded due to insufficient exposure to an ACE inhibitor (<1 year, according to our a priori definitions). Thus, our final analysis included 6,176 subjects, 1,187 patients in the ACE inhibitor cohort and 4,989 in the control cohort.

Sociodemographic data and a modified comorbidity index, the Chronic Disease Score (CDS), were also collected. The CDS provides an indication of the burden of concurrent comorbidities by identifying specific drug therapies during the follow-up period (16–18). The CDS is well validated, and higher scores are associated with increased mortality, hospitalization rates, and health resource utilization (16–18). A modified CDS was used in this analysis, which was updated to include a wider range of marker drugs than originally identified and has been previously utilized with this dataset (11).

Outcomes

Our primary study outcomes were all-cause and cardiovascular-related mortality. Health services data for the cohorts were followed prospectively for identification and classification of clinical events from the study index date until death, departure from the province, or 31 December 1999. The underlying cause of death was documented by trained coders who applied World Health Organization (WHO) standardized decision rules. Specific ICD-9 codes for cardiovascular-related mortality were identified (online appendix).

Analysis

Using Cox proportional hazards regression models, crude and adjusted hazard ratios (HRs) and 95% CIs were calculated to assess the relationship between ACE inhibitor use and outcomes. Potential confounding variables included in the multivariate model included age, sex, a modified CDS, insulin therapy, and other drug therapies known to affect cardiovascular outcomes (i.e., lipid-lowering drugs, β-blockers, calcium channel blockers, antiplatelet agents, diuretics, antiarrhythmics, metformin, and nitroglycerin). In addition, all potentially clinically important first-order interactions were assessed in the Cox proportional hazards model; no important or statistically significant (P < 0.10) interactions were identified.

In addition, to adjust for potential selection bias, we calculated a propensity score intended to represent the likelihood of receiving one of the treatments given the individual’s characteristics and included this as a covariate in the primary multivariate models (19–21). The inclusion of the propensity score in the analysis, however, made no significant difference in the point estimates obtained (i.e., <2% change in point estimates) or our conclusions; thus, only the simpler primary multivariate models are presented here.

RESULTS

The mean (±SD) age for all subjects was 60.7 ± 13.7 years and 56.4% were men (Table 1). The mean (±SD) duration of follow-up was 5.3 ± 2.1 years, for a total of >32,000 patient-years. The ACE inhibitor cohort was somewhat younger, contained fewer men, had a longer duration of follow-up, greater comorbidities, and significantly more prescription claims for cardiovascular- and diabetes-related medications compared with the control group (Table 1). The mean duration of exposure to ACE inhibitor therapy was 3.6 ± 1.9 years (range 1.0–8.8).

There were 853 (17.1%) deaths in the control group compared with 102 (8.6%) in the ACE inhibitor group (P < 0.001). Of these, 261 (5.2%) cardiovascular-related deaths occurred in the control group and 40 (3.4%) in the ACE inhibitor group (P = 0.007). The unadjusted HR (95% CI) for all-cause and cardiovascular-related mortality were 0.43 (0.35–0.52, P < 0.001) and 0.54 (0.39–0.76, P < 0.001), respectively (Table 2).

The adjusted HRs (95% CI), after controlling for age, sex, CDS, and drug therapies known to affect cardiovascular outcomes, were 0.49 (0.40–0.61, P < 0.001) for all-cause and 0.63 (0.44–0.90, P = 0.012) for cardiovascular-related mortality (Table 2). The adjusted survival curves for all-cause and cardiovascular-related mortality appeared similar, separating early and continuing to diverge throughout the follow-up period (Fig. 1).

CONCLUSIONS

Our results suggest that the use of ACE inhibitor therapy in a broad spectrum of patients with newly treated type 2 diabetes is associated with a reduction in all-cause and cardiovascular-related mortality. After adjusting for important clinical variables, we observed a 51% reduction in all-cause mortality and a 23% reduction in cardiovascular-related mortality. In absolute terms, we estimate that 12 newly treated patients with type 2 diabetes would need to be treated with an ACE inhibitor for about 4 years to prevent one death.

These results are generally consistent with those observed in other studies (22–24) evaluating ACE inhibitor therapy in people with diabetes. Direct comparison with other trials is difficult, however, due to different study methods, comparative treatments under study, patient populations, and clinical outcomes assessed. Of the studies completed to date, the HOPE study most closely resembles the patient population and outcomes of interest in our analysis. In the main HOPE study (8), ramipril significantly lowered the risk of all-cause and cardiovascular-related death. In the participants of HOPE who had diabetes (n = 3,577 [38%]), there was a 24 and 37% relative risk reduction in all-cause and cardiovascular-related mortality, respectively, for patients who received ramipril (9). Subgroup analysis of those patients without cardiovascular disease at baseline (n = 1,119) showed no significant benefit of ramipril. In contrast, our study suggests that ACE inhibitors are associated with significant mortality benefits in the lower-risk subgroup of patients with type 2 diabetes and no clinical cardiovascular disease.

The strengths of our study include the inclusiveness of the population (i.e., a broad population of people with diabetes), the comprehensiveness of the database, and the long and consistent duration of follow-up. The Saskatchewan Health databases have been used in numerous epidemiological studies (11,25–27) evaluating outcomes with drug use and are considered to be comprehensive and of high quality. Nevertheless, given the observational nature of the analyses, several alternative explanations are possible. We did not have access to clinical information regarding the baseline cardiovascular risk and modifiable cardiovascular risk factors of the subjects (e.g., glycemic control, hypertension, lipids, renal function, smoking, and BMI). It is possible that subjects in the ACE inhibitor group had a lower baseline risk for all-cause and cardiovascular-related mortality. Control for these factors was possible to a certain extent by examining only newly treated subjects with diabetes and excluding all subjects who had a history of cardiovascular disease or had a prescription claim for a product containing nitroglycerin or a loop diuretic. Furthermore, we adjusted all analyses for a well-validated measure of comorbidity (16–18). Finally, we observed that subjects in the ACE inhibitor cohort used more cardiovascular-related medications compared with the control cohort. We have interpreted this to mean that they may have had a greater burden of cardiovascular disease and, therefore, increased overall cardiovascular risk. If this were the case, in the absence of a true ACE inhibitor benefit, we might have observed an increased risk of mortality in the ACE inhibitor cohort. Our interpretation of an increased cardiovascular risk in the ACE inhibitor cohort is supported by the observed greater use of nitrates, a symptomatic treatment, which was independently associated with an increased risk of cardiovascular events.

We also attempted to control for comorbidities unrelated to diabetes and cardiovascular disease by including the modified CDS in the multivariate analysis. Again, patients in the ACE inhibitor group had greater comorbidities and would have been expected to have a greater risk of mortality. We acknowledge that not all comorbidities would be captured with the use of the CDS; however, a significant proportion of the major comorbidities that affect patient outcomes was captured (16–18).

There are limitations inherent to all administrative data. Since exposure status was based on prescription dispensing records, there is no method to ensure that subjects were adherent with their medications. All subjects in the ACE inhibitor group had to have received ACE inhibitors for a minimum of 1 year and, on average, for almost 4 years. It is unlikely subjects would continue to refill and bear the expense burden associated with these prescriptions if they were not taking the medication.

Our study suggests that ACE inhibitors can be used by many newly treated patients with type 2 diabetes and that this practice may be associated with reduced mortality. As it is unlikely that a randomized controlled trial of ACE inhibitor verses placebo therapy in patients with diabetes will ever be undertaken, our observational data may provide the best available evidence that many patients with diabetes will derive substantial mortality benefits from the routine use of ACE inhibitors.

Figure 1—
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1—

Adjusted Kaplan-Meier survival curves for clinical outcomes in patients with type 2 diabetes, stratified by ACE inhibitor exposure. A: All-cause mortality. B: Cardiovascular-related mortality. Black line, ACE inhibitor cohort; gray line, control cohort.

View this table:
  • View inline
  • View popup
Table 1—

Characteristics of 6,176 newly treated patients with type 2 diabetes

View this table:
  • View inline
  • View popup
Table 2—

Mortality rates in patients with type 2 diabetes according to ACE inhibitor exposure

Acknowledgments

This study was funded in part by grants from the Alberta Heritage Foundation for Medical Research (AHFMR) and the Institute of Health Economics. This work was supported by a New Emerging Team (NET) grant to the Alliance for Canadian Health Outcomes in Diabetes (ACHORD). The ACHORD NET grant is sponsored by the Canadian Diabetes Association, the Heart and Stroke Foundation of Canada, The Kidney Foundation of Canada, the CIHR-Institute of Nutrition, Metabolism and Diabetes, and the CIHR-Institute of Circulatory and Respiratory Health.

D.T.E. holds a Full-time Studentship in Health Research with AHFMR. J.A.J. and S.R.M. are Population Health Investigators with the AHFMR. S.R.M. is a New Investigator of the Canadian Institutes of Health Research. J.A.J. holds a Canada Research Chair in Diabetes Health Outcomes.

Footnotes

  • Additional information for this article can be found in an online appendix at http://care.diabetesjournals.org.

    This study is based in part on de-identified data provided by the Saskatchewan Department of Health. The interpretation and conclusions contained herein do not necessarily represent those of the Government of Saskatchewan or the Saskatchewan Department of Health.

    A table elsewhere in this issue shows conventional and Système International (SI) units and conversion factors for many substances.

    • Accepted March 12, 2004.
    • Received February 19, 2004.
  • DIABETES CARE

References

  1. ↵
    Erkens JA, Herings RM, Stolk RP, Spoelstra JA, Grobbee DE, Leufkens HG: Cardiovascular risk factors and diseases precede oral hypoglycaemic therapy in patients with type 2 diabetes mellitus. J Clin Epidemiol 55:345–349, 2002
    OpenUrlPubMed
  2. ↵
    Huang ES, Meigs JB, Singer DE: The effect of interventions to prevent cardiovascular disease in patients with type 2 diabetes mellitus. Am J Med 111:633–642, 2001
    OpenUrlCrossRefPubMedWeb of Science
  3. ↵
    Expert Committee on the Diagnosis and Classification of Diabetes Mellitus: Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 23 (Suppl. 1):S4–S19, 2000
    OpenUrlPubMed
  4. ↵
    Meltzer S, Leiter L, Daneman D, Gerstein HC, Lau D, Ludwig S, Yale JF, Zinman B, Lillie D: 1998 clinical practice guidelines for the management of diabetes in Canada: Canadian Diabetes Association. CMAJ 159 (Suppl.):S1–S29, 1998
  5. ↵
    Lonn EM, Yusuf S, Jha P, Montague TJ, Teo KK, Benedict CR, Pitt B: Emerging role of angiotensin-converting enzyme inhibitors in cardiac and vascular protection. Circulation 90:2056–2069, 1994
    OpenUrlFREE Full Text
  6. Sleight P: Angiotensin II and trials of cardiovascular outcomes. Am J Cardiol 89:11A–16A, 2002
    OpenUrlCrossRefPubMedWeb of Science
  7. ↵
    EUROPA Investigators: Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 362:782–788, 2003
    OpenUrlCrossRefPubMedWeb of Science
  8. ↵
    Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G: Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients: the Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 342:145–153, 2000
    OpenUrlCrossRefPubMedWeb of Science
  9. ↵
    Heart Outcomes Prevention Evaluation (HOPE) Study Investigators: Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy: Heart Outcomes Prevention Evaluation Study Investigators. Lancet 355:253–259, 2000
    OpenUrlCrossRefPubMedWeb of Science
  10. ↵
    Downey W, Beck P, McNutt M, Stang M, Osei W, Nichol J: Health databases in Saskatchewan. In Pharmacoepidemiology. 3rd ed. Strom BL, Ed. Chichester, U.K., John Wiley and Sons, 2000, p. 325–345
  11. ↵
    Johnson JA, Majumdar SR, Simpson SH, Toth EL: Decreased mortality associated with metformin use compared to sulfonylurea monotherapy in type 2 diabetes mellitus. Diabetes Care 25:2244–2248, 2002
    OpenUrlAbstract/FREE Full Text
  12. ↵
    Tsuyuki RT, Olson KL, Teo KK: Nitroglycerin as an indicator for the presence of coronary heart disease. Can Pharm J 132:32–36, 1999
    OpenUrl
  13. Connolly P, Cupples ME, Cuene-Grandidier H, Johnston D, Passmore P: The importance of validating the diagnosis of coronary heart disease when measuring secondary prevention: a cross-sectional study in general practice. Pharmacoepidemiol Drug Saf 11:311–317, 2002
    OpenUrlCrossRefPubMedWeb of Science
  14. Turner CJ, Parfrey P, Ryan K, Miller R, Brown A: Community pharmacist outreach program directed at physicians treating congestive heart failure. Am J Health Syst Pharm 57:747–752, 2000
    OpenUrlAbstract/FREE Full Text
  15. ↵
    Udris EM, Au DH, McDonell MB, Chen L, Martin DC, Tierney WM, Fihn SD: Comparing methods to identify general internal medicine clinic patients with chronic heart failure. Am Heart J 142:1003–1009, 2001
    OpenUrlCrossRefPubMedWeb of Science
  16. ↵
    Clark DO, Von Korff M, Saunders K, Baluch WM, Simon GE: A chronic disease score with empirically derived weights. Med Care 33:783–795, 1995
    OpenUrlCrossRefPubMedWeb of Science
  17. Johnson RE, Hornbrook MC, Nichols GA: Replicating the chronic disease score (CDS) from automated pharmacy data. J Clin Epidemiol 47:1191–1199, 1994
    OpenUrlCrossRefPubMedWeb of Science
  18. ↵
    Von Korff M, Wagner EH, Saunders K: A chronic disease score from automated pharmacy data. J Clin Epidemiol 45:197–203, 1992
    OpenUrlCrossRefPubMedWeb of Science
  19. ↵
    D’Agostino RB Jr: Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med 17:2265–2281, 1998
    OpenUrlCrossRefPubMedWeb of Science
  20. Rosenbaum PR, Rubin DB: The central role of the propensity score in observational studies for causal effects. Biometrika 70:41–55, 1983
    OpenUrlAbstract/FREE Full Text
  21. ↵
    Rubin DB: Estimating causal effects from large data sets using propensity scores. Ann Intern Med 127:757–763, 1997
    OpenUrlCrossRefPubMedWeb of Science
  22. ↵
    Gustafsson I, Torp-Pedersen C, Kober L, Gustafsson F, Hildebrandt P: Effect of the angiotensin-converting enzyme inhibitor trandolapril on mortality and morbidity in diabetic patients with left ventricular dysfunction after acute myocardial infarction: Trace Study Group. J Am Coll Cardiol 34:83–89, 1999
    OpenUrlCrossRefPubMedWeb of Science
  23. Vijan S, Hayward RA: Treatment of hypertension in type 2 diabetes mellitus: blood pressure goals, choice of agents, and setting priorities in diabetes care. Ann Intern Med 138:593–602, 2003
    OpenUrlCrossRefPubMedWeb of Science
  24. ↵
    Zuanetti G, Latini R, Maggioni AP, Franzosi M, Santoro L, Tognoni G: Effect of the ACE inhibitor lisinopril on mortality in diabetic patients with acute myocardial infarction: data from the GISSI-3 study. Circulation 96:4239–4245, 1997
    OpenUrlAbstract/FREE Full Text
  25. ↵
    Ray WA, Griffin MR, Downey W: Benzodiazepines of long and short elimination half-life and the risk of hip fracture. JAMA 262:3303–3307, 1989
    OpenUrlCrossRefPubMedWeb of Science
  26. Spitzer WO, Suissa S, Ernst P, Horwitz RI, Habbick B, Cockcroft D, Boivin JF, McNutt M, Buist AS, Rebuck AS: The use of beta-agonists and the risk of death and near death from asthma. N Engl J Med 326:501–506, 1992
    OpenUrlCrossRefPubMedWeb of Science
  27. ↵
    Suissa S, Ernst P, Benayoun S, Baltzan M, Cai B: Low-dose inhaled corticosteroids and the prevention of death from asthma. N Engl J Med 343:332–336, 2000
    OpenUrlCrossRefPubMedWeb of Science
PreviousNext
Back to top
Diabetes Care: 27 (6)

In this Issue

June 2004, 27(6)
  • Table of Contents
  • About the Cover
  • Index by Author
Sign up to receive current issue alerts
View Selected Citations (0)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about Diabetes Care.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Reduced Mortality Associated With the Use of ACE Inhibitors in Patients With Type 2 Diabetes
(Your Name) has forwarded a page to you from Diabetes Care
(Your Name) thought you would like to see this page from the Diabetes Care web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Reduced Mortality Associated With the Use of ACE Inhibitors in Patients With Type 2 Diabetes
Dean T. Eurich, Sumit R. Majumdar, Ross T. Tsuyuki, Jeffrey A. Johnson
Diabetes Care Jun 2004, 27 (6) 1330-1334; DOI: 10.2337/diacare.27.6.1330

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Add to Selected Citations
Share

Reduced Mortality Associated With the Use of ACE Inhibitors in Patients With Type 2 Diabetes
Dean T. Eurich, Sumit R. Majumdar, Ross T. Tsuyuki, Jeffrey A. Johnson
Diabetes Care Jun 2004, 27 (6) 1330-1334; DOI: 10.2337/diacare.27.6.1330
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • RESEARCH DESIGN AND METHODS
    • RESULTS
    • CONCLUSIONS
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Tables
  • Suppl Material
  • Info & Metrics
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Autologous Umbilical Cord Blood Transfusion in Young Children With Type 1 Diabetes Fails to Preserve C-Peptide
  • Effects of MK-0941, a Novel Glucokinase Activator, on Glycemic Control in Insulin-Treated Patients With Type 2 Diabetes
  • Diabetes Antibody Standardization Program
Show more Emerging Treatments and Technologies

Similar Articles

Navigate

  • Current Issue
  • Standards of Care Guidelines
  • Online Ahead of Print
  • Archives
  • Submit
  • Subscribe
  • Email Alerts
  • RSS Feeds

More Information

  • About the Journal
  • Instructions for Authors
  • Journal Policies
  • Reprints and Permissions
  • Advertising
  • Privacy Policy: ADA Journals
  • Copyright Notice/Public Access Policy
  • Contact Us

Other ADA Resources

  • Diabetes
  • Clinical Diabetes
  • Diabetes Spectrum
  • Scientific Sessions Abstracts
  • Standards of Medical Care in Diabetes
  • BMJ Open - Diabetes Research & Care
  • Professional Books
  • Diabetes Forecast

 

  • DiabetesJournals.org
  • Diabetes Core Update
  • ADA's DiabetesPro
  • ADA Member Directory
  • Diabetes.org

© 2021 by the American Diabetes Association. Diabetes Care Print ISSN: 0149-5992, Online ISSN: 1935-5548.